You just read:

ImmunoMet Announces Initiation of Phase 1 Clinical Study of IM156, an OXPHOS Inhibitor, in Patients with Solid Tumors

News provided by

ImmunoMet Therapeutics

Oct 03, 2017, 08:30 ET